This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Giuseppe (Pino) Ciaramella, Ph.D.
President and Chief Scientific Officer at BeamTherapeutics


Dr Giuseppe Ciaramella is the President and Chief Scientific Officer of Beam Therapeutics. Ciaramella has more than 25 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck. Throughout his career he has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Prior to joining Beam Therapeutics, Dr Ciaramella was the CSO of the Infectious Diseases division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans, several of which are progressing through clinical studies. At Astrazeneca, he he set up and led the company’s small molecule antiviral strategy and led a team developing a novel cephalosporin antibiotic, in collaboration with a Korean company. At Boehringer Ingelheim, he served as Vice President and Head of Collaborative Research where he had responsibility for external R&D and was a member of the Research Leadership Team. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the UK where he held several Discovery leadership positions, including head of Biotherapeutics, head of Antivirals and head of Lead Discovery. He has contributed to several clinical candidates, both small molecule and biologics and to the anti-HIV drug Maraviroc (Selzentry TM), which won the USA Prix Galien for Best Pharmaceutical in 2008. Dr. Ciaramella is the first or second author on 12 granted patents and on several other pending patents and has contributed to more than 30 manuscripts. He is a member of the Infectious Diseases Society of America (IDSA) and of the American Society of Gene Therapy (ASGT). He holds a PhD in Biochemistry and Molecular Biology from University College London.

Agenda Sessions

  • Therapeutic Applications of Base Editing